patients with ANL this may be disease related. 
Further research is needed to characterize the populations of cells in peripheral blood 
stimulated by various cytokines in vivo and to define optimal doses of cytokines and ways to optimize 
PBSC harvest An important cell to define is the repopulating hematopoietic stem celL At this time 
stem cell quantity, at least in marrow, is most reliably predicted by the number of cells which express 
the CD 34 antigen (33). Sustained pluripotent engraftment was produced in baboons after lethal 
irradiation and infusion of only 3.2-4.4 x 10* cells/kg. of CD34+ cells (34). Transplants performed 
without selecting CD34+ cells require significantly more cells (^lxlO'/kg.) to achieve sustained 
engraftment suggesting that the stem cell concentration is greater within the CD34 population. In vitro, 
another method being used to estimate the presence of stem cells is to assume that the number of blast 
cell colonies correlates with that of more mature progenitors such as CFU-GM and BFU-E. Juttner, et 
a L have shown a 1:1 correlation of CD34+ cells with CFU-GM concentration in peripheral blood. 
However, more work needs to be done to characterize progenitors in peripheral blood after cytokine 
administration. 
This study proposes to evaluate the administration of cryopreserved peripheral blood cells 
collected after the administration of rhG-CSF and administered with cryopreserved bone marrow 
followed by the administration of rhG-CSF. These results will be compared to patients who have 
received marrow alone followed by rhG-CSF after myeloablative therapy in a subsequent study. This 
study is designed to take advantage of the additional committed progenitor cell load supplied by the . 
peripheral blood cells in an attempt to resolve the significant period of pancytopenia after autologous 
B.MT, while relying on the more pluripotent stem cells, assumed to be present in marrow, for long term 
hematopoetic reconstitution. 
This study is the first of 3 sequential studies to compare the efficacy of various growth factors in 
stimulating the mobilization of peripheral blood stem cells. Protocol 531 involves IL-3 and a protocol 
will be written for stem cell factor when this drug is approved for use in humans by the FDA. The 
finical aspects of this study utilize unstimulated bone marrow stem cells to produce stable sustained 
engraftment and G-CSF stimulated peripheral blood committed progenitor cells to produce early 
engraftment. 
4. Objectives 
A. To study hematopoietic precursor cell characteristics in peripheral blood before and after 
G-CSF administration. These will include the measurement of CD34 + cells, colony 
forming cells and colony forming cell precursors. 
B. To evaluate toxicity of G-CSF stimulated peripheral blood cell administration with 
marrow. 
C. To determine the time to achieve an ANC of 100, 500 and 1,000 platelets to 20,000/mm 3 
in patients receiving peripheral blood cells plus marrow followed by rhG-CSF. 
5. Patient Selection 
A. Inclusion criteria 
1. Patients with Hodgkin’s Disease (HD) or non-Hodgkin’s lymphomas (NHL) who 
are eligible to undergo ABMT ut ilizin g active FHCRC protocols. 
2. Patients with no circulating malignant cells by histologic analysis. 
3. There are no age, sex, and prior therapy limitations. However, patients must be 
of sufficient size (> 100#) to be able to undergo apheresis. 
4. There is no exclusion for monoclonal antibody purged marrow. 
5. Signed informed consent conforming to FDA and institutional guidelines is 
required. 
[344] 
Recombinant DNA Research, Volume 16 
